Replimune Group, Inc.
REPLReplimune Group, Inc. is a biotechnology company focused on developing proprietary immunotherapies for cancer treatment. Its cathepsin-based oncolytic immunotherapies aim to activate the immune system to recognize and destroy tumors, with a focus on combining these therapies with other cancer treatments to enhance efficacy.
Company News
The Schall Law Firm is investigating Replimune Group, Inc. for potential securities law violations related to allegedly false or misleading statements. The company received a complete response letter from the FDA regarding its BLA for RP1 in combination with nivolumab for advanced melanoma treatment, citing disagreement over data suitability. Fol...
The global oncolytic virus immunotherapy market is projected to reach over $5 billion by 2031, with three approved therapies and more than 150 candidates in clinical trials. Major pharmaceutical companies and biotechnology firms are advancing combination therapies and strategic partnerships to address cancer treatment challenges, with significant...
Replimune announced it received a Complete Response Letter (CRL) from the FDA for its RP1 biologics license application in combination with nivolumab for advanced melanoma treatment. Despite the drug showing a 34% response rate with 24.8-month median duration in the IGNYTE trial, the FDA rejected approval. The company criticized the FDA's regulat...
The global oncolytic virotherapy market is projected to grow from USD 49.73 million in 2025 to USD 153.31 million by 2031, with a CAGR of 20.64%. Growth is driven by rising cancer incidence, advances in genetic engineering, and synergistic combination therapies with checkpoint inhibitors. However, host immune system challenges and premature viral...
Replimune presented biomarker data showing RP1 plus nivolumab can potentially reverse resistance mechanisms to PD-1 blockade in advanced melanoma, demonstrating a 33.6% response rate and 24.8-month median response duration.
